Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Emily Lutterloh is active.

Publication


Featured researches published by Emily Lutterloh.


The Lancet | 2009

H1N1 2009 influenza virus infection during pregnancy in the USA

Denise J. Jamieson; Margaret A. Honein; Sonja A. Rasmussen; Jennifer Williams; David L. Swerdlow; Matthew Biggerstaff; Stephen Lindstrom; Janice K. Louie; Cara M Christ; Susan Bohm; Vincent P. Fonseca; Kathleen A. Ritger; Daniel J Kuhles; Paula Eggers; Hollianne Bruce; Heidi Davidson; Emily Lutterloh; Meghan Harris; Colleen Burke; Noelle Cocoros; Lyn Finelli; Kitty MacFarlane; Bo Shu; Sonja J. Olsen

BACKGROUND Pandemic H1N1 2009 influenza virus has been identified as the cause of a widespread outbreak of febrile respiratory infection in the USA and worldwide. We summarised cases of infection with pandemic H1N1 virus in pregnant women identified in the USA during the first month of the present outbreak, and deaths associated with this virus during the first 2 months of the outbreak. METHODS After initial reports of infection in pregnant women, the US Centers for Disease Control and Prevention (CDC) began systematically collecting additional information about cases and deaths in pregnant women in the USA with pandemic H1N1 virus infection as part of enhanced surveillance. A confirmed case was defined as an acute respiratory illness with laboratory-confirmed pandemic H1N1 virus infection by real-time reverse-transcriptase PCR or viral culture; a probable case was defined as a person with an acute febrile respiratory illness who was positive for influenza A, but negative for H1 and H3. We used population estimates derived from the 2007 census data to calculate rates of admission to hospital and illness. FINDINGS From April 15 to May 18, 2009, 34 confirmed or probable cases of pandemic H1N1 in pregnant women were reported to CDC from 13 states. 11 (32%) women were admitted to hospital. The estimated rate of admission for pandemic H1N1 influenza virus infection in pregnant women during the first month of the outbreak was higher than it was in the general population (0.32 per 100 000 pregnant women, 95% CI 0.13-0.52 vs 0.076 per 100 000 population at risk, 95% CI 0.07-0.09). Between April 15 and June 16, 2009, six deaths in pregnant women were reported to the CDC; all were in women who had developed pneumonia and subsequent acute respiratory distress syndrome requiring mechanical ventilation. INTERPRETATION Pregnant women might be at increased risk for complications from pandemic H1N1 virus infection. These data lend support to the present recommendation to promptly treat pregnant women with H1N1 influenza virus infection with anti-influenza drugs. FUNDING US CDC.


Clinical Infectious Diseases | 2012

Multidrug-Resistant Typhoid Fever With Neurologic Findings on the Malawi-Mozambique Border

Emily Lutterloh; Andrew Likaka; James J. Sejvar; Robert Manda; Jeremias Naiene; Stephan S. Monroe; Tadala Khaila; Benson Chilima; Macpherson Mallewa; Sam Kampondeni; Sara A. Lowther; Linda Capewell; Kashmira Date; David Townes; Yanique Redwood; Joshua G. Schier; Benjamin Nygren; Beth A. Tippett Barr; Austin Demby; Abel Phiri; Rudia Lungu; James Kaphiyo; Michael Humphrys; Deborah F. Talkington; Kevin Joyce; Lauren J. Stockman; Gregory L. Armstrong; Eric D. Mintz

BACKGROUND Salmonella enterica serovar Typhi causes an estimated 22 million cases of typhoid fever and 216 000 deaths annually worldwide. We investigated an outbreak of unexplained febrile illnesses with neurologic findings, determined to be typhoid fever, along the Malawi-Mozambique border. METHODS The investigation included active surveillance, interviews, examinations of ill and convalescent persons, medical chart reviews, and laboratory testing. Classification as a suspected case required fever and ≥1 other finding (eg, headache or abdominal pain); a probable case required fever and a positive rapid immunoglobulin M antibody test for typhoid (TUBEX TF); a confirmed case required isolation of Salmonella Typhi from blood or stool. Isolates underwent antimicrobial susceptibility testing and subtyping by pulsed-field gel electrophoresis (PFGE). RESULTS We identified 303 cases from 18 villages with onset during March-November 2009; 214 were suspected, 43 were probable, and 46 were confirmed cases. Forty patients presented with focal neurologic abnormalities, including a constellation of upper motor neuron signs (n = 19), ataxia (n = 22), and parkinsonism (n = 8). Eleven patients died. All 42 isolates tested were resistant to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole; 4 were also resistant to nalidixic acid. Thirty-five of 42 isolates were indistinguishable by PFGE. CONCLUSIONS The unusual neurologic manifestations posed a diagnostic challenge that was resolved through rapid typhoid antibody testing in the field and subsequent blood culture confirmation in the Malawi national reference laboratory. Extending laboratory diagnostic capacity, including blood culture, to populations at risk for typhoid fever in Africa will improve outbreak detection, response, and clinical treatment.


Morbidity and Mortality Weekly Report | 2017

Notes from the Field: Ongoing Transmission of Candida auris in Health Care Facilities — United States, June 2016–May 2017

Sharon Tsay; Rory M. Welsh; Eleanor Adams; Nancy A. Chow; Lalitha Gade; Elizabeth L. Berkow; Eugenie Poirot; Emily Lutterloh; Monica Quinn; Sudha Chaturvedi; Janna L Kerins; Stephanie Black; Sarah Kemble; Patricia M Barrett; Kerri Barton; Dj Shannon; Kristy K Bradley; Shawn R. Lockhart; Anastasia P. Litvintseva; Heather Moulton-Meissner; Alicia Shugart; Alex Kallen; Snigdha Vallabhaneni; Tom Chiller; Brendan R. Jackson

Ongoing Transmission of Candida auris in Health Care Facilities — United States, June 2016–May 2017 Sharon Tsay, MD1,2; Rory M. Welsh, PhD1; Eleanor H. Adams, MD3; Nancy A. Chow, PhD1; Lalitha Gade, MPharm1; Elizabeth L. Berkow, PhD1; Eugenie Poirot, PhD2,4; Emily Lutterloh, MD3,5; Monica Quinn, MS3; Sudha Chaturvedi, PhD3,5; Janna Kerins, VMD2,6; Stephanie R. Black, MD6; Sarah K. Kemble, MD6; Patricia M. Barrett, MSD7; Kerri Barton, MPH8; D.J. Shannon, MPH9; Kristy Bradley, DVM10; Shawn R. Lockhart, PhD1; Anastasia P. Litvintseva, PhD1; Heather MoultonMeissner, PhD11; Alicia Shugart, MA11; Alex Kallen, MD11; Snigdha Vallabhaneni, MD1; Tom M. Chiller, MD1; Brendan R. Jackson, MD1


Public Health Reports | 2011

Carbon Monoxide Poisoning After an Ice Storm in Kentucky, 2009

Emily Lutterloh; Shahed Iqbal; Jacquelyn H. Clower; Henry A. Spiller; Margaret A. Riggs; Tennis J. Sugg; Kraig E. Humbaugh; Betsy L. Cadwell; Douglas Thoroughman

Objectives. Carbon monoxide (CO) poisoning is a leading cause of morbidity and mortality during natural disasters. On January 26–27, 2009, a severe ice storm occurred in Kentucky, causing widespread, extended power outages and disrupting transportation and communications. After the storm, CO poisonings were reported throughout the state. The objectives of this investigation were to determine the extent of the problem, identify sources of CO poisoning, characterize cases, make recommendations to reduce morbidity and mortality, and develop prevention strategies. Methods. We obtained data from the Kentucky Regional Poison Center (KRPC), hyperbaric oxygen treatment (HBOT) facilities, and coroners. Additionally, the Kentucky Department for Public Health provided statewide emergency department (ED) and hospitalization data. Results. During the two weeks after the storm, KRPC identified 144 cases of CO poisoning; exposure sources included kerosene heaters, generators, and propane heaters. Hospitals reported 202 ED visits and 26 admissions. Twenty-eight people received HBOT. Ten deaths were attributed to CO poisoning, eight of which were related to inappropriate generator location. Higher rates of CO poisoning were reported in areas with the most ice accumulation. Conclusions. Although CO poisonings are preventable, they continue to occur in postdisaster situations. Recommendations include encouraging use of CO alarms, exploring use of engineering controls on generators to decrease CO exposure, providing specific information regarding safe use and placement of CO-producing devices, and using multiple communication methods to reach people without electricity.


PLOS ONE | 2012

Neurologic Manifestations Associated with an Outbreak of Typhoid Fever, Malawi - Mozambique, 2009: An Epidemiologic Investigation

James J. Sejvar; Emily Lutterloh; Jeremias Naiene; Andrew Likaka; Robert Manda; Benjamin Nygren; Stephan S. Monroe; Tadala Khaila; Sara A. Lowther; Linda Capewell; Kashmira Date; David Townes; Yanique Redwood; Joshua G. Schier; Beth A. Tippett Barr; Austin Demby; Macpherson Mallewa; Sam Kampondeni; Ben Blount; Michael Humphrys; Deborah F. Talkington; Gregory L. Armstrong; Eric D. Mintz

Background The bacterium Salmonella enterica serovar Typhi causes typhoid fever, which is typically associated with fever and abdominal pain. An outbreak of typhoid fever in Malawi-Mozambique in 2009 was notable for a high proportion of neurologic illness. Objective Describe neurologic features complicating typhoid fever during an outbreak in Malawi-Mozambique Methods Persons meeting a clinical case definition were identified through surveillance, with laboratory confirmation of typhoid by antibody testing or blood/stool culture. We gathered demographic and clinical information, examined patients, and evaluated a subset of patients 11 months after onset. A sample of persons with and without neurologic signs was tested for vitamin B6 and B12 levels and urinary thiocyanate. Results Between March – November 2009, 303 cases of typhoid fever were identified. Forty (13%) persons had objective neurologic findings, including 14 confirmed by culture/serology; 27 (68%) were hospitalized, and 5 (13%) died. Seventeen (43%) had a constellation of upper motor neuron findings, including hyperreflexia, spasticity, or sustained ankle clonus. Other neurologic features included ataxia (22, 55%), parkinsonism (8, 20%), and tremors (4, 10%). Brain MRI of 3 (ages 5, 7, and 18 years) demonstrated cerebral atrophy but no other abnormalities. Of 13 patients re-evaluated 11 months later, 11 recovered completely, and 2 had persistent hyperreflexia and ataxia. Vitamin B6 levels were markedly low in typhoid fever patients both with and without neurologic signs. Conclusions Neurologic signs may complicate typhoid fever, and the diagnosis should be considered in persons with acute febrile neurologic illness in endemic areas.


Clinical Infectious Diseases | 2016

Transmission of Balamuthia mandrillaris by Organ Transplantation.

Eileen C. Farnon; Kenneth E. Kokko; Philip J. Budge; Chukwuma Mbaeyi; Emily Lutterloh; Yvonne Qvarnstrom; Alexandre J. da Silva; Wun-Ju Shieh; Sharon L. Roy; Christopher D. Paddock; Rama Sriram; Sherif R. Zaki; Govinda S. Visvesvara; Matthew J. Kuehnert

BACKGROUND During 2009 and 2010, 2 clusters of organ transplant-transmitted Balamuthia mandrillaris, a free-living ameba, were detected by recognition of severe unexpected illness in multiple recipients from the same donor. METHODS We investigated all recipients and the 2 donors through interview, medical record review, and testing of available specimens retrospectively. Surviving recipients were tested and treated prospectively. RESULTS In the 2009 cluster of illness, 2 kidney recipients were infected and 1 died. The donor had Balamuthia encephalitis confirmed on autopsy. In the 2010 cluster, the liver and kidney-pancreas recipients developed Balamuthia encephalitis and died. The donor had a clinical syndrome consistent with Balamuthia infection and serologic evidence of infection. In both clusters, the 2 asymptomatic recipients were treated expectantly and survived; 1 asymptomatic recipient in each cluster had serologic evidence of exposure that decreased over time. Both donors had been presumptively diagnosed with other neurologic diseases prior to organ procurement. CONCLUSIONS Balamuthia can be transmitted through organ transplantation with an observed incubation time of 17-24 days. Clinicians should be aware of Balamuthia as a cause of encephalitis with high rate of fatality, and should notify public health departments and evaluate transplant recipients from donors with signs of possible encephalitis to facilitate early diagnosis and targeted treatment. Organ procurement organizations and transplant centers should be aware of the potential for Balamuthia infection in donors with possible encephalitis and also assess donors carefully for signs of neurologic infection that may have been misdiagnosed as stroke or as noninfectious forms of encephalitis.


American Journal of Infection Control | 2015

Effect of 2013 National Healthcare Safety Network definition changes on central line bloodstream infection rates: Audit results from the New York State Department of Health

Peggy Ann Hazamy; Valerie B. Haley; Boldtsetseg Tserenpuntsag; Marie Tsivitis; Rosalie Giardina; Robin Knab; Emily Lutterloh

Surveillance criteria for central line-associated bloodstream infections (CLABSIs) are continually being refined to more accurately reflect infections related to central lines. An audit of 567 medical records from adult, pediatric, and neonatal intensive care unit patients with a central line and a positive blood culture showed a 16% decrease in CLABSI rates after the 2013 National Healthcare Safety Network definitions compared with the 2012 definitions.


Emerging Infectious Diseases | 2018

Candida auris in Healthcare Facilities, New York, USA, 2013–2017

Eleanor Adams; Monica Quinn; Sharon Tsay; Eugenie Poirot; Sudha Chaturvedi; Karen Southwick; Jane Greenko; Rafael Fernandez; Alex Kallen; Snigdha Vallabhaneni; Valerie B. Haley; Brad Hutton; Debra Blog; Emily Lutterloh; Howard Zucker; Candida auris Investigation Workgroup

Candida auris is an emerging yeast that causes healthcare-associated infections. It can be misidentified by laboratories and often is resistant to antifungal medications. We describe an outbreak of C. auris infections in healthcare facilities in New York City, New York, USA. The investigation included laboratory surveillance, record reviews, site visits, contact tracing with cultures, and environmental sampling. We identified 51 clinical case-patients and 61 screening case-patients. Epidemiologic links indicated a large, interconnected web of affected healthcare facilities throughout New York City. Of the 51 clinical case-patients, 23 (45%) died within 90 days and isolates were resistant to fluconazole for 50 (98%). Of screening cultures performed for 572 persons (1,136 total cultures), results were C. auris positive for 61 (11%) persons. Environmental cultures were positive for samples from 15 of 20 facilities. Colonization was frequently identified during contact investigations; environmental contamination was also common.


Lancet Infectious Diseases | 2018

Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the USA: a molecular epidemiological survey

Nancy A. Chow; Lalitha Gade; Sharon Tsay; Kaitlin Forsberg; Jane Greenko; Karen Southwick; Patricia M Barrett; Janna L Kerins; Shawn R. Lockhart; Tom Chiller; Anastasia P. Litvintseva; Eleanor Adams; Kerri Barton; Karlyn D. Beer; Meghan L. Bentz; Elizabeth L. Berkow; Stephanie Black; Kristy K Bradley; Richard Brooks; Sudha Chaturvedi; Whitney Clegg; Melissa Cumming; Alfred DeMaria; Nychie Dotson; Erin E. Epson; Rafael Fernandez; Tara Fulton; Rebecca Greeley; Brendan R. Jackson; Sarah Kemble

BACKGROUND Transmission of multidrug-resistant Candida auris infection has been reported in the USA. To better understand its emergence and transmission dynamics and to guide clinical and public health responses, we did a molecular epidemiological investigation of C auris cases in the USA. METHODS In this molecular epidemiological survey, we used whole-genome sequencing to assess the genetic similarity between isolates collected from patients in ten US states (California, Connecticut, Florida, Illinois, Indiana, Maryland, Massachusetts, New Jersey, New York, and Oklahoma) and those identified in several other countries (Colombia, India, Japan, Pakistan, South Africa, South Korea, and Venezuela). We worked with state health departments, who provided us with isolates for sequencing. These isolates of C auris were collected during the normal course of clinical care (clinical cases) or as part of contact investigations or point prevalence surveys (screening cases). We integrated data from standardised case report forms and contact investigations, including travel history and epidemiological links (ie, patients that had shared a room or ward with a patient with C auris). Genetic diversity of C auris within a patient, a facility, and a state were evaluated by pairwise differences in single-nucleotide polymorphisms (SNPs). FINDINGS From May 11, 2013, to Aug 31, 2017, isolates that corresponded to 133 cases (73 clinical cases and 60 screening cases) were collected. Of 73 clinical cases, 66 (90%) cases involved isolates related to south Asian isolates, five (7%) cases were related to South American isolates, one (1%) case to African isolates, and one (1%) case to east Asian isolates. Most (60 [82%]) clinical cases were identified in New York and New Jersey; these isolates, although related to south Asian isolates, were genetically distinct. Genomic data corroborated five (7%) clinical cases in which patients probably acquired C auris through health-care exposures abroad. Among clinical and screening cases, the genetic diversity of C auris isolates within a person was similar to that within a facility during an outbreak (median SNP difference three SNPs, range 0-12). INTERPRETATION Isolates of C auris in the USA were genetically related to those from four global regions, suggesting that C auris was introduced into the USA several times. The five travel-related cases are examples of how introductions can occur. Genetic diversity among isolates from the same patients, health-care facilities, and states indicates that there is local and ongoing transmission. FUNDING US Centers for Disease Control and Prevention.


Infection Control and Hospital Epidemiology | 2016

Healthcare-Associated Transmission of Plasmodium falciparum in New York City.

Ellen H. Lee; Eleanor Adams; Susan Madison-Antenucci; Lillian V. Lee; John W. Barnwell; Joan Whitehouse; Ernest J. Clement; Waheed I. Bajwa; Lucretia Jones; Emily Lutterloh; Don Weiss; Joel Ackelsberg

A patient with no risk factors for malaria was hospitalized in New York City with Plasmodium falciparum infection. After investigating all potential sources of infection, we concluded the patient had been exposed to malaria while hospitalized less than 3 weeks earlier. Molecular genotyping implicated patient-to-patient transmission in a hospital setting. Infect. Control Hosp. Epidemiol. 2015;37(1):113-115.

Collaboration


Dive into the Emily Lutterloh's collaboration.

Top Co-Authors

Avatar

Eleanor Adams

New York State Department of Health

View shared research outputs
Top Co-Authors

Avatar

Jane Greenko

New York State Department of Health

View shared research outputs
Top Co-Authors

Avatar

Karen Southwick

New York State Department of Health

View shared research outputs
Top Co-Authors

Avatar

Beth A. Tippett Barr

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Ernest J. Clement

New York State Department of Health

View shared research outputs
Top Co-Authors

Avatar

James J. Sejvar

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Joshua G. Schier

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Monica Quinn

New York State Department of Health

View shared research outputs
Top Co-Authors

Avatar

Sharon Tsay

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Stephan S. Monroe

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge